HK1203379A1 - Arrestin effectors and compositions and methods of use thereof - Google Patents

Arrestin effectors and compositions and methods of use thereof

Info

Publication number
HK1203379A1
HK1203379A1 HK15103956.9A HK15103956A HK1203379A1 HK 1203379 A1 HK1203379 A1 HK 1203379A1 HK 15103956 A HK15103956 A HK 15103956A HK 1203379 A1 HK1203379 A1 HK 1203379A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
arrestin effectors
arrestin
effectors
Prior art date
Application number
HK15103956.9A
Other languages
English (en)
Chinese (zh)
Inventor
Xiao Tao Chen
Dennis Yamashita
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of HK1203379A1 publication Critical patent/HK1203379A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15103956.9A 2012-01-31 2015-04-23 Arrestin effectors and compositions and methods of use thereof HK1203379A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592887P 2012-01-31 2012-01-31
PCT/US2013/023808 WO2013116312A1 (en) 2012-01-31 2013-01-30 ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
HK1203379A1 true HK1203379A1 (en) 2015-10-30

Family

ID=48870731

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103956.9A HK1203379A1 (en) 2012-01-31 2015-04-23 Arrestin effectors and compositions and methods of use thereof

Country Status (14)

Country Link
US (2) US8946142B2 (de)
EP (1) EP2809337A4 (de)
JP (1) JP6225121B2 (de)
KR (1) KR20140132340A (de)
CN (1) CN104168907A (de)
AU (1) AU2013215269A1 (de)
BR (1) BR112014018709A8 (de)
CA (1) CA2862933A1 (de)
EA (1) EA201491455A1 (de)
HK (1) HK1203379A1 (de)
IL (1) IL233826A0 (de)
MX (1) MX2014009233A (de)
NZ (1) NZ627995A (de)
WO (1) WO2013116312A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013215269A1 (en) * 2012-01-31 2014-08-21 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
EP3208861A1 (de) 2016-02-19 2017-08-23 Novaled GmbH Elektronentransportschicht mit einer matrixverbindungsmischung für eine organische leuchtdiode (oled)
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925345A (en) * 1974-05-10 1975-12-09 Francis Merlin Bumpus (sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4547489A (en) 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
EP0358418B1 (de) * 1988-09-05 1992-12-16 Sankyo Company Limited Cyclisches Peptid, seine Herstellung und seine Verwendung zur Behandlung von cardiovasculären Störungen
GB8822483D0 (en) 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JPH06500323A (ja) 1990-08-27 1994-01-13 ペプチド　テクノロジィ　リミテッド ウイルス性感染の治療方法
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
AU706333B2 (en) 1993-09-24 1999-06-17 University Of Southern California Use of angiotensin III and analogs thereof in tissue repair
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
JP4347522B2 (ja) 1997-12-12 2009-10-21 ユニバーシティ オブ サザン カリフォルニア 創傷治癒組成物
US20040214836A1 (en) 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20050202029A1 (en) 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
US8038992B2 (en) 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
DK2376101T3 (en) * 2008-12-29 2016-01-18 Trevena Inc BETA-arrestin effectors AND COMPOSITIONS AND METHODS FOR USE THEREOF
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
JP5925771B2 (ja) * 2010-06-24 2016-05-25 トラスティーズ オブ タフツ カレッジ ナイアシン模倣体、およびその使用方法
AU2013215269A1 (en) * 2012-01-31 2014-08-21 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof

Also Published As

Publication number Publication date
JP2015506960A (ja) 2015-03-05
EP2809337A1 (de) 2014-12-10
US20150105316A1 (en) 2015-04-16
MX2014009233A (es) 2015-05-15
AU2013215269A1 (en) 2014-08-21
EA201491455A1 (ru) 2015-01-30
IL233826A0 (en) 2014-09-30
CA2862933A1 (en) 2013-08-08
EP2809337A4 (de) 2016-05-11
CN104168907A (zh) 2014-11-26
US20130196902A1 (en) 2013-08-01
KR20140132340A (ko) 2014-11-17
JP6225121B2 (ja) 2017-11-01
BR112014018709A8 (pt) 2017-07-11
NZ627995A (en) 2016-12-23
WO2013116312A1 (en) 2013-08-08
US8946142B2 (en) 2015-02-03
BR112014018709A2 (de) 2017-06-20

Similar Documents

Publication Publication Date Title
HK1212729A1 (zh) 核糖核酸調節子組合物和使用方法
HK1207001A1 (en) Immunostimulatory compositions and methods of use thereof
HK1215785A1 (zh) 控制釋放組合物及使用方法
EP2834322A4 (de) Biokohlezusammensetzungen und verfahren zur verwendung davon
EP2836224A4 (de) Zusammensetzungen von biozönose und zugehörige verfahren
EP2675471A4 (de) Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren
SG11201501499SA (en) Multi-functional compositions and methods of use
EP2836218A4 (de) Probiotische zusammensetzungen und verfahren zur verwendung
EP2536756A4 (de) Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren
EP2584897A4 (de) Resveratrolhaltige zusammensetzungen und verfahren zu ihrer verwendung
EP2912178A4 (de) Superverstärker und verfahren zur verwendung davon
EP2654726A4 (de) Festdispersionsformulierungen und verwendungsverfahren dafür
HK1212251A1 (en) Topical compositions and methods of use
EP2596112A4 (de) Acetycystein-zusammensetzungen und verwendungsverfahren dafür
EP2667889A4 (de) Wnt-zusammensetzungen und verwendungsverfahren dafür
EP2897639A4 (de) Verbesserte impfstoffzusammensetzungen und verfahren zur verwendung
HK1209031A1 (en) Polysaccharide compositions and methods of use
EP2906041A4 (de) Zusammensetzungen und verfahren zur verwendung in einer inappetenzsteuerungsverbindung
EP2807256A4 (de) Myonectin (ctrp15), zusammensetzungen damit und verwendungsverfahren
HK1213151A1 (zh) 葉黃素組合物及使用方法
EP2852370A4 (de) Strahlungszusammensetzungen und verfahren zur verwendung
ZA201406267B (en) Controlled release compositions and their methods of use
HK1203379A1 (en) Arrestin effectors and compositions and methods of use thereof
IL233961B (en) The composition of a phytogenic supplement and methods of its use
EP2859071A4 (de) Chemische zusammensetzungen und verfahren zur verwendung davon